Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of GoodwillAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Share-based Compensation (2016 - 2025)

Avanos Medical (AVNS) has disclosed Share-based Compensation for 13 consecutive years, with $1.2 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation fell 68.42% to $1.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $12.6 million through Dec 2025, down 8.7% year-over-year, with the annual reading at $12.6 million for FY2025, 8.7% down from the prior year.
  • Share-based Compensation hit $1.2 million in Q4 2025 for Avanos Medical, down from $3.5 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $4.1 million in Q3 2022 to a low of $1.2 million in Q4 2025.
  • Historically, Share-based Compensation has averaged $3.6 million across 5 years, with a median of $3.8 million in 2022.
  • Biggest YoY gain for Share-based Compensation was 34.62% in 2025; the steepest drop was 68.42% in 2025.
  • Year by year, Share-based Compensation stood at $3.0 million in 2021, then skyrocketed by 33.33% to $4.0 million in 2022, then changed by 0.0% to $4.0 million in 2023, then fell by 5.0% to $3.8 million in 2024, then tumbled by 68.42% to $1.2 million in 2025.
  • Business Quant data shows Share-based Compensation for AVNS at $1.2 million in Q4 2025, $3.5 million in Q3 2025, and $4.1 million in Q2 2025.